



Amphilimus™(Sirolimus + Fatty Acid) eluting Peripheral Self-Expanding stent

> The ILLUMINA study: 2 years results

> > **Pr. D. Scheinert**

Disclosure

Speaker name:

I have the following potential conflicts of interest to report:

- Consulting
- Employment in industry
- Stockholder of a healthcare company
- Owner of a healthcare company
- Other(s)

] I do not have any potential conflict of interest



ILLUMINA study design

Innovative siroLimus seLf expanding drUg-eluting stent for the treatMent of perIpheral disease: evaluation of safety aNd efficAcy

Patients over 18 years with ischemic obstruction of superficial femoral arteries and proximal popliteal arteries due to de novo or restenotic lesion(s) and no prior stent in the target lesion

Prospective, Single arm 10 centers in Europe (n= 100 pts) Prof. Dierk Scheinert (Coordinating Clinical Investigator, Leipzig-Germany) eCRFs; Core Lab; CEC



ILLUMINA study design

Innovative siroLimus seLf expanding drUg-eluting stent for the treatMent of perIpheral disease: evaluation of safety aNd efficAcy

Primary Endpoint:

- SAFETY: Composite event –free survival at 12 months: Freedom from CEC adjudicated MAE (death, target limb amputation, target limb ischemia requiring surgical intervention or surgical repair of target vessel or clinically-driven target lesion revascularization) and freedom from worsening of the Rutherford score by 2 classes, or to class 5 or 6
 - **EFFICACY: Primary patency at 12 months.** Primary patency is defined as absence of clinicallydriven target lesion revascularization or binary restenosis. Binary restenosis is defined as a peak systolic velocity ratio (PSVR) >2.4 (duplex evaluation)

Main Secondary Endpoints:

Technical Success

- Composite event-free survival and primary patency rate at 6 and 24 months follow-up
- Clinically driven TLR at 6, 12 and 24 months

ILLUMINA study centers and enrolled pts.


	Clinical Sites		Patients	Country	Pts per Country
	Universitätsklinikum Leipzig	Scheinert	3	Germany	46
	Universitäts-Herzzentrum Freiburg Bad Krozingen	Zeller	13		
	Regiomed GefäBzentrum Sonneberg	Thieme	13		
	St. Gertrauden Krankenhaus GmbH - Berlin	Langhoff	17		
	San Raffaele Hospital - Milan	Chiesa/Kahlberg	15	Italy	19
	Maria Cecilia Hospital - Cotignola	Cremonesi	2		
	Fondazione IRCCS Policlinico San Matteo - Pavia	Marone	2		
	Clinique Pasteur - Toulouse	Sauguet	24	France	35
	Polyclinique Les Fleurs - Ollioules	Commeau	3		
	Centre Prive Claude Galien - Quincy	Garot	8		
	Total		100		

?Alvimedica


ILLUMINA study patients baselines

2020

T



ILLUMINA study lesions characteristics





ILLUMINA study procedural results

Procedural results

Stent deployment success: 100% Procedural success: 100% Stent per patient [n]: 1.09 ± 0.32 Total mean length of stent [mm]: 86.7 ± 40.8

ILLUMINA 24 months study results: Safety


6	6
3	0
0	0
1	0
1	1 (0)
11	7 (6)
	3 0 1 1 1




*1 death due to Myocardial Infarction @ 5 months - non stent or procedural related (CEC adjudicated)
1 death due to severe septic shock @ 13 months - non stent or procedural related (CEC adjudicated)
1 death due to lung cancer @ 17 months - non stent or procedural related (CEC adjudicated)

1 thrombo-endo-arterectomy (far proximal to the lesion - CRFA) @ 18 months - non stent related (CEC adjudicated) *Patient, asymptomatic at 1year, had femoral fracture 5months before 2years FU visit (Rutherford classes are not CEC adjudicated)


ILLUMINA 24 months study results: Safety



ILLUMINA 24 months study results: Efficacy




ILLUMINA 24 months study results: TLR



ILLUMINA study results in perspective:

When referring to "Freedom from Major Adverse Events (MAE)", the ILLUMINA study results well compare to the outcomes of other DES studies recently released.





ILLUMINA study results in perspective:

Similarly, referring to "**TLR**", the excellent NiTiDES efficacy challenges Eluvia's performance at 2years.





ILLUMINA study conclusions

- NiTiDES represents the first and only Sirolimus eluting self-expanding peripheral stent today available.
- Although the ILLUMINA study included complex patients and complex lesions (2pts Rutherford 5, lesions up to 140mm and 55% of mod./ heavy calcifications), the study results at 24 months are remarkable:
 - ▷ SAFETY → 91.9% Freedom from device related MAE confirms the long term excellent performance of the NiTiDES device.
 - ▷ EFFICACY → 93.1% Freedom from TLR and 83.4% Primary Patency rate demonstrate that the high product efficacy is maintained over long time.
- The ILLUMINA study results stand NiTiDES at the top of excellence in today peripheral DES scenario.



www.alvimedica.com